Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s share price traded up 6.4% on Wednesday . The company traded as high as $27.05 and last traded at $27.01. 188,103 shares traded hands during trading, a decline of 79% from the average session volume of 905,464 shares. The stock had previously closed at $25.38.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on MTSR shares. Bank of America started coverage on shares of Metsera in a report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Wells Fargo & Company started coverage on shares of Metsera in a report on Friday. They set an "overweight" rating and a $65.00 price objective on the stock. Evercore ISI started coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "outperform" rating on the stock. Finally, Guggenheim upped their target price on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $55.00.
Read Our Latest Report on Metsera
Metsera Trading Up 6.8%
The business's 50 day moving average price is $25.70.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Institutional Trading of Metsera
Large investors have recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in shares of Metsera during the first quarter valued at approximately $76,000. New York State Common Retirement Fund bought a new position in Metsera in the 1st quarter worth approximately $131,000. Corebridge Financial Inc. acquired a new position in Metsera during the 1st quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Metsera in the 1st quarter valued at $248,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Metsera in the 1st quarter valued at $254,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
